Epigral Ltd.'s FY26 ESG Report

Epigral Ltd., a specialty chemicals manufacturer, has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. This comprehensive filing details the company's commitment to environmental, social, and governance (ESG) principles, providing investors with insight into its operational framework.

As part of the DCM Shriram Group, Epigral focuses on producing chemicals for diverse sectors, including agriculture, pharmaceuticals, and industrial applications. The report outlines its operational data, such as energy consumption and waste generation, alongside future sustainability goals and its approach to stakeholder engagement and employee well-being.

For FY 2025-26, Epigral reported consuming 16,587.21 Giga Joules of energy and generating 97,671.27 Metric tonnes of waste. Looking ahead, the company is working towards carbon neutrality by 2050 and aims to increase its use of renewable energy to 50% by 2028. Efforts are also focused on improving waste utilization efficiency and maximizing resource recovery.

The filing also identifies significant risks inherent in the chemical manufacturing sector. These include potential penalties from emissions of greenhouse gases, SOx, NOx, and hazardous air pollutants, as well as risks associated with water scarcity, such as increased procurement prices and capital expenditure. Improper handling of hazardous chemicals and inadequate waste management pose substantial environmental and health risks, carrying the potential for heavy fines and reputational damage. Epigral also faces challenges from regulatory scrutiny and competition if innovative environmental impact management is not adopted, alongside compliance and business ethics concerns.

This focus on sustainability and risk disclosure aligns with trends seen among major Indian specialty chemical players like Aarti Industries Ltd. and Deepak Nitrite Ltd., who are also increasingly highlighting their ESG initiatives. Investors will be closely tracking Epigral's progress toward its stated targets and how it addresses the operational and compliance risks outlined in the report.